Showing 6531-6540 of 7745 results for "".
- Water's Edge Partners with Goodman Dermatologyhttps://practicaldermatology.com/news/waters-edge-partners-with-goodman-dermatology/2460837/Water’s Edge Dermatology has partnered with Goodman Dermatology, P.C., a general and cosmetic dermatology practice in Atlanta. Water’s Edge Dermatology recently merged with Riverchase Dermatology (collectively, “WED/RCD”) and is a leading provider of compreh
- Dermavant Submits NDA for Tapinarof for PsOhttps://practicaldermatology.com/news/dermavant-submits-nda-for-tapinarof-for-pso/2460820/Dermavant Sciences has submitted a New Drug Application (NDA) to the FDA for tapinarof for the treatment of mild, moderate, and severe plaque psoriasis in adult patients. Tapinarof is a novel, therapeutic aryl hydrocarbon receptor modulating agent, in development as a once-daily,
- BioFactura Starts Phase I Study of BFI-751, a Stelara Biosimilarhttps://practicaldermatology.com/news/biofactura-starts-phase-i-study-of-bfi-751-a-stelara-biosimilar/2460811/BioFactura is set to begin a pivotal pharmacokinetics Phase 1 clinical trial for its Ustekinumab biosimilar BFI-751. The first-in-human Phase I study will assess the effects on healthy human volunteers compared to the biologic medicine, Stelara. This is the first time BFI-751 has been a
- Meet PDO Max's New Executive Hireshttps://practicaldermatology.com/news/meet-pdo-maxs-new-executive-hires/2460810/Dina BenDavid is the new Director of Training and Clinical Development at PDO Max. BenDavid is a board-certified nurse practitioner, holds both a Master's and Doctoral degrees, and is a professor of nursing and clinical trainer in medical aesthetics. She is founder and owner of
- Medivir’s Remetinostat Shows Promise for SCChttps://practicaldermatology.com/news/medivirs-remetinostat-shows-promise-for-scc/2460807/Topical remetinostat gel performed well in a small investigator-initiated phase II clinical study of patients with squamous cell carcinoma. Four patients with five cutaneous SCCs were included in this case series and treated with remetinostat gel 1%. All five tumors, including
- Lotrimin Taps WWE Superstar and Soles4Souls to Kick Foot Shame to the Curb and Encourage People to #GoWithConfidencehttps://practicaldermatology.com/news/lotrimin-taps-wwe-superstar-and-soles4souls-to-kick-foot-shame-to-the-curb-and-encourage-people-to-gowithconfidence/2460805/Lotrimin is teaming up with WWE Superstar The Miz to educate people on healthy feet habits and help people from all walks of life to #GoWithConfidence through a partnership with Soles4Souls – a nonprofit organization that turns unwanted shoes and clothing into opportunities for people in ne
- Cetaphil Launches Mineral Sunscreen Line, Kicks Off Educational Campaignhttps://practicaldermatology.com/news/cetaphil-launches-mineral-sunscreen-line-kicks-off-educational-campaign/2460794/Cetaphil is kicking off a campaign to help educate the public about sun safety to help prevent skin cancer. Throughout the month of May, Cetaphil and its leading dermatologist ambassadors will be dedicated to maximizing awareness of the symptoms, ca
- FDA Nod for Modifications to Soliton's Resonic Devicehttps://practicaldermatology.com/news/fda-nod-for-modifications-to-solitons-tattoo-removal-device/2460790/The U.S. Food and Drug Administration granted Soliton, Inc. 510(k) for modifications to its RESONIC device. The RESONIC device utilizes the RAP technology to deliver safe and effective tattoo removal and cellulite treatment and now includes an autoloading cartridge and an
- Potential Regenerative Medicine Breakthrough: Mayo Clinic Preclinical Discovery Triggers Scar-free Wound Healinghttps://practicaldermatology.com/news/potential-regenerative-medicine-breakthrough-mayo-clinic-preclinical-discovery-triggers-scar-free-wound-healing/2460788/Difficult-to-treat, chronic wounds in preclinical models healed with normal scar-free skin after treatment with an acellular product discovered at Mayo Clinic. Derived from platelets, the purified exosomal product, known as PEP, was used to deliver healing messages into cells of p
- UCB: Bimekizumab PDUFA Date Set for Octoberhttps://practicaldermatology.com/news/ucb-bimekizumab-pdufa-set-for-october/2460787/The FDA's Prescription Drug User Fee Act (PDUFA) date for UCB’s Biologics License Application (BLA) for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis is October 15, 2021, UCB has indicated. In a